The Swiss Society of Nephrology (SGN) advocates targeted screening for defined risk groups. However, given the prevalence of chronic kidney disease (CKD) in primary care, it is hardly possible to refer everyone affected to a nephrologist. Clear risk stratification is therefore essential. Drug therapy is based on several pillars and aims to slow down the rate of progression of GFR decline on the one hand and to reduce the cardiovascular risk on the other.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Secondary prevention after ACS: individually optimized lipid management
Trend towards early combination therapy and new strategies for lowering Lp(a)
- Pediatric Brain Tumors
Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls
- What the latest studies on the entire EF spectrum mean for clinical practice
Heart Failure – The 2026 Evidence Update
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment
SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes
- Wearables: screening via smartwatch?
New study on atrial fibrillation in high-risk patients
- Peristomal skin health
Focus on preventive care options
- Planning a Family, Pregnancy, and Breastfeeding